[go: up one dir, main page]

MX343580B - Anticuerpos contra el g-csfr y sus usos. - Google Patents

Anticuerpos contra el g-csfr y sus usos.

Info

Publication number
MX343580B
MX343580B MX2013014711A MX2013014711A MX343580B MX 343580 B MX343580 B MX 343580B MX 2013014711 A MX2013014711 A MX 2013014711A MX 2013014711 A MX2013014711 A MX 2013014711A MX 343580 B MX343580 B MX 343580B
Authority
MX
Mexico
Prior art keywords
csfr
antibodies against
antibodies
bind
present disclosure
Prior art date
Application number
MX2013014711A
Other languages
English (en)
Other versions
MX2013014711A (es
Inventor
Donald Nash Andrew
Elizabeth Andrews Arna
Mae Edwards Kirsten
Philip Hardy Matthew
Panousis Con
Dunlop Felicity
Baca Manuel
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47353852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343580(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of MX2013014711A publication Critical patent/MX2013014711A/es
Publication of MX343580B publication Critical patent/MX343580B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a proteínas que comprenden dominios de unión a antígenos de anticuerpos que se unen al receptor del factor estimulador de colonias de granulocitos humano.
MX2013014711A 2011-06-13 2012-06-13 Anticuerpos contra el g-csfr y sus usos. MX343580B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496351P 2011-06-13 2011-06-13
PCT/AU2012/000675 WO2012171057A1 (en) 2011-06-13 2012-06-13 Antibodies against g-csfr and uses thereof

Publications (2)

Publication Number Publication Date
MX2013014711A MX2013014711A (es) 2014-09-01
MX343580B true MX343580B (es) 2016-11-10

Family

ID=47353852

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014711A MX343580B (es) 2011-06-13 2012-06-13 Anticuerpos contra el g-csfr y sus usos.

Country Status (15)

Country Link
US (6) US9193793B2 (es)
EP (1) EP2718326B1 (es)
JP (1) JP6187777B2 (es)
KR (1) KR101822702B1 (es)
CN (1) CN103649123B (es)
AU (1) AU2012269720B2 (es)
BR (1) BR112013031943B1 (es)
CA (1) CA2838246C (es)
DK (1) DK2718326T3 (es)
ES (1) ES2828482T3 (es)
IL (1) IL229468B (es)
MX (1) MX343580B (es)
RU (1) RU2605595C2 (es)
SG (1) SG195043A1 (es)
WO (1) WO2012171057A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838246C (en) 2011-06-13 2018-07-10 Csl Limited Antibodies against g-csfr and uses thereof
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
JP7046173B2 (ja) * 2017-10-11 2022-04-01 エランコ・ユーエス・インコーポレイテッド ブタｇ－ｃｓｆ変異体とその使用
AU2018377856B2 (en) 2017-11-29 2025-01-09 Csl Limited Method of treating or preventing ischemia-reperfusion injury
US20210009677A1 (en) * 2018-03-23 2021-01-14 Csl Limited Method of treating asthma
PT3618928T (pt) 2018-07-13 2023-03-29 Alector Llc Anticorpos anti-sortilina e métodos de utilização dos mesmos
AU2019393334A1 (en) * 2018-12-04 2021-06-10 CSL Innovation Pty Ltd Method of treating neutrophilic conditions
US20220305133A1 (en) * 2019-06-12 2022-09-29 CSL Innovation Pty., Ltd. Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof
CN114901684A (zh) * 2019-10-08 2022-08-12 酵活有限公司 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子
WO2021243424A1 (en) * 2020-06-04 2021-12-09 CSL Innovation Pty Ltd Method of treating or preventing acute respiratory distress syndrome
JP2023554087A (ja) * 2020-12-16 2023-12-26 シーエスエル イノベーション プロプライアタリー リミティド タンパク質製剤及びその使用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
DE69334258D1 (de) 1992-08-21 2009-02-26 Univ Bruxelles Immunoglobuline ohne Leichtkette
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
AUPM375194A0 (en) 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2374534T3 (es) 1998-03-20 2012-02-17 Commonwealth Scientific And Industrial Research Organisation Control de la expresión de genes.
EP1068311B2 (en) 1998-04-08 2020-12-09 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
PT1390535E (pt) 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
AUPR544401A0 (en) 2001-06-04 2001-06-28 Bischof, Robert Juergen Animal model for allergy
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
CA2527726A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
WO2005003156A1 (en) 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
EP2330121B1 (en) 2004-06-02 2014-09-03 AdAlta Pty Ltd Binding moieties based on Shark IgNAR domains
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
EP2267030A1 (en) 2005-08-25 2010-12-29 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
WO2008003763A1 (en) * 2006-07-06 2008-01-10 Laboratoires Serono Sa Csf3r polypeptides and uses thereof
AU2007283463B2 (en) * 2006-08-11 2012-04-26 Csl Limited Treatment of pulmonary disease conditions
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
KR101940059B1 (ko) 2008-12-19 2019-01-18 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
CA2773552C (en) * 2009-09-15 2017-11-21 Csl Limited Treatment of neurological conditions
US8968731B2 (en) * 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
ES2678144T3 (es) 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
CN102869777B (zh) 2010-04-02 2018-11-02 库尔纳公司 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
EP2675471A4 (en) 2011-02-15 2015-01-28 Medimmune Llc HSA-RELATED COMPOSITIONS AND USE PROCESSES
CA2838246C (en) 2011-06-13 2018-07-10 Csl Limited Antibodies against g-csfr and uses thereof
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9050305B2 (en) 2012-03-29 2015-06-09 Chs Pharma, Inc. Treatment for ischemic stroke
JP6487328B2 (ja) 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
MX2016010729A (es) 2014-02-21 2016-10-26 Genentech Inc Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
US10336821B2 (en) 2014-11-17 2019-07-02 Csl Limited Method of treating stroke by administering a compound that inhibits VEGF-B signaling in combination with a thrombolytic agent
RU2018139893A (ru) 2016-04-21 2020-05-21 СиЭсЭл ЛИМИТЕД Способ лечения или предупреждения болезней печени
AU2018377856B2 (en) 2017-11-29 2025-01-09 Csl Limited Method of treating or preventing ischemia-reperfusion injury
KR20190073917A (ko) 2017-12-19 2019-06-27 포항공과대학교 산학협력단 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물
US20210009677A1 (en) 2018-03-23 2021-01-14 Csl Limited Method of treating asthma
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
BR112021008873A8 (pt) 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
AU2019393334A1 (en) 2018-12-04 2021-06-10 CSL Innovation Pty Ltd Method of treating neutrophilic conditions
US20220305133A1 (en) 2019-06-12 2022-09-29 CSL Innovation Pty., Ltd. Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof

Also Published As

Publication number Publication date
DK2718326T3 (da) 2020-10-26
EP2718326B1 (en) 2020-08-19
CN103649123B (zh) 2017-05-24
RU2605595C2 (ru) 2016-12-20
US20160031998A1 (en) 2016-02-04
RU2014100642A (ru) 2015-07-20
AU2012269720B2 (en) 2015-01-22
SG195043A1 (en) 2013-12-30
MX2013014711A (es) 2014-09-01
ES2828482T3 (es) 2021-05-26
CN103649123A (zh) 2014-03-19
BR112013031943B1 (pt) 2021-10-13
WO2012171057A1 (en) 2012-12-20
US20190055313A1 (en) 2019-02-21
US9193793B2 (en) 2015-11-24
IL229468B (en) 2021-05-31
US12071484B2 (en) 2024-08-27
CA2838246A1 (en) 2012-12-20
US20170226214A1 (en) 2017-08-10
CA2838246C (en) 2018-07-10
JP6187777B2 (ja) 2017-08-30
BR112013031943A2 (pt) 2016-11-22
US20250051462A1 (en) 2025-02-13
JP2014519517A (ja) 2014-08-14
KR101822702B1 (ko) 2018-01-26
IL229468A0 (en) 2014-01-30
KR20140041717A (ko) 2014-04-04
AU2012269720A1 (en) 2013-03-21
EP2718326A1 (en) 2014-04-16
NZ617725A (en) 2015-02-27
US20210009701A1 (en) 2021-01-14
EP2718326A4 (en) 2015-07-08
US20120321630A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
MX343580B (es) Anticuerpos contra el g-csfr y sus usos.
EP4219552A3 (en) Il-11r binding proteins and uses thereof
MY160590A (en) Cd127 binding proteins
PH12013502378A1 (en) Fc RECEPTOR BINDING PROTEINS
PH12014502527A1 (en) St2 antigen binding proteins
IN2014CN03042A (es)
MX2019006902A (es) Inmunoglobulinas heterodimericas.
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
NZ626610A (en) Antibodies that bind csf1r
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
EA201400579A1 (ru) Антитела к il-36r
MX358367B (es) Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos.
NZ604510A (en) Dilutable biocidal compositions and methods of use
WO2012006341A3 (en) Anti-ron antibodies
MX2014004326A (es) Anticuerpos a cd1d.
PH12013500616A1 (en) Antibody compositions and methods of use
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
NZ757754A (en) Antibodies that bind csf1r
NZ621320A (en) Anti-human xcr1 antibodies

Legal Events

Date Code Title Description
FG Grant or registration